Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
about
β-hairpin-mediated formation of structurally distinct multimers of neurotoxic prion peptidesConformational equilibria in monomeric alpha-synuclein at the single-molecule levelGenetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation updateCa2+ binding to alpha-synuclein regulates ligand binding and oligomerizationMagnesium inhibits spontaneous and iron-induced aggregation of alpha-synucleinAcceleration of alpha-synuclein aggregation by homologous peptidesSynaptic vesicle trafficking and Parkinson's diseaseA ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of ParkinFK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53TMolecular determinants of α-synuclein mutants' oligomerization and membrane interactionsParkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradationPre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease modelsThe N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranesp25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathiesSecondary structure and dynamics of micelle bound beta- and gamma-synucleinMolecules that cause or prevent Parkinson's diseaseSequence determinants of protein aggregation: tools to increase protein solubility.Parkin counteracts symptoms in a Drosophila model of Parkinson's disease.Dynamic structural flexibility of α-synucleinTranscriptional mutagenesis by 8-oxodG in α-synuclein aggregation and the pathogenesis of Parkinson's diseaseElectrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomicsExploring the accessible conformations of N-terminal acetylated α-synucleinNeuropathological alterations in Alzheimer diseaseMitochondrial dysfunction and oxidative stress in Parkinson's diseaseUbiquitous amyloidsPropagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neuronsAmitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activityCharacteristics of Amyloid-Related Oligomers Revealed by Crystal Structures of Macrocyclic β-Sheet MimicsAmyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicityAlpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body DisordersAlpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical ApplicationSeeking a mechanism for the toxicity of oligomeric α-synucleinEngineering enhanced protein disaggregases for neurodegenerative disease14-3-3eta is a novel regulator of parkin ubiquitin ligase.L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome systemParkin cleaves intracellular alpha-synuclein inclusions via the activation of calpainalpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson diseaseIn vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's diseaseThe aetiology of idiopathic Parkinson's disease
P2860
Q21558493-DA728567-3E21-4A9F-9FF3-C16D47356E70Q21563559-04FAE119-D08F-45D5-906C-34A89FCB5777Q22252904-E21FC63E-72C8-45BF-AA75-D34EE6DEE482Q24291150-46203FF4-BD55-48A7-AD01-75758FEB0092Q24292317-16CF29B5-0AC3-41AB-8BB1-6FF45491933DQ24293132-2BD5A368-3D62-4576-A9E2-18F5A2B3BB1DQ24302024-C25C5ED8-95BD-4C20-8A9A-9C0CEDE517F8Q24308676-3D84C02A-6E13-4367-95E0-2A931146D23BQ24311758-643A15B3-69B4-4131-B1CA-702C0907909DQ24312185-A7BC49A5-DC0A-49CC-A93E-B5C9037C36DDQ24312713-F0F9573E-61E9-4733-B449-8B8B21AEB679Q24315670-446DA62F-8F58-49CB-85C1-AA709A3FA63AQ24316619-135CC769-F685-4585-AFB1-E095A9917873Q24320549-CFDCBACC-C293-4B59-AD44-54CA4E806681Q24647859-9BABBE29-1412-4C09-80E8-5E3F7DCAA21FQ24793714-114D1A07-FC35-4CAD-B74D-D94B3ED5893EQ24795353-D285926C-C4EC-4509-A6F0-962885930BC5Q24803129-F1BD007C-5B60-4F6C-8F26-B867F9247EA6Q26770060-64CFD3B5-4F87-4419-8BEF-4D08BE4F5A68Q26796502-D5600C54-A12B-4353-B857-15C388D65EA9Q26822552-BAA5F05C-0D22-452F-8A63-03A56F7799E0Q26852660-14A45845-5BC6-4433-A55E-BA7DEA724687Q27003314-835FC156-81C1-4934-9154-95055A2B4858Q27014051-DE3AA09A-A7EB-4CA9-BD4B-6EE793D337E0Q27016014-EC0F8BB7-A6CB-4785-AD9B-27D4D89E55E3Q27322513-4BA5070B-0FDD-41DC-9ED8-E8EA9DA5415FQ27332460-438D575B-0F23-4288-95FF-D9908DAA15FCQ27334070-2751774A-5A19-483C-8190-2E247A4CFAAAQ27667459-277A5375-ACCD-41E0-9721-EB0E0E620E62Q27674676-E9C5A867-E51A-4A48-910F-F64FA2DDE755Q28067429-E77259B3-349A-4075-86C6-AF38BA6C1A4DQ28079911-03694282-56EF-411F-9A4B-F687E9563D83Q28080551-743C86E8-8BEC-4FD1-9948-A8EC71F13639Q28083809-80E63D50-468F-4484-8899-53A69A5D0E8CQ28115387-84AF6839-68E4-402B-8F30-A1CBF40F02E0Q28185988-6CBCB851-95CD-4EBF-BF4A-785F19512EBCQ28201602-A1DFD9F3-1031-445C-B356-3F97C2E3379EQ28264682-9C7E2C95-1EB3-40A4-BFB6-D641005BCA13Q28363291-AAD2EE61-2DA5-4A17-8134-625686DD5C9DQ28365451-D272B501-821A-4ED6-AB5D-6C204683BC90
P2860
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@ast
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@en
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@nl
type
label
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@ast
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@en
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@nl
altLabel
Acceleration of oligomerizatio ...... s for pathogenesis and therapy
@en
prefLabel
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@ast
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@en
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@nl
P2093
P2860
P921
P356
P1476
Acceleration of oligomerizatio ...... for pathogenesis and therapy.
@en
P2093
J C Rochet
K A Conway
P T Lansbury
R E Williamson
P2860
P304
P356
10.1073/PNAS.97.2.571
P407
P577
2000-01-01T00:00:00Z